corifollitropin alfa + GnRH antagonist

This therapeutic regimen is used in controlled ovarian stimulation (COS) for women undergoing assisted reproductive technology (ART), such as in vitro fertilization (IVF). It specifically combines **corifollitropin alfa**, a long-acting recombinant follicle-stimulating hormone (FSH) analog, with a gonadotropin-releasing hormone (GnRH) antagonist (such as ganirelix or cetrorelix). Corifollitropin alfa is a fusion protein that maintains circulating FSH levels above the threshold necessary to support multi-follicular growth for an entire week with a single injection, thereby reducing the treatment burden compared to daily FSH injections. The GnRH antagonist is administered to prevent premature luteinizing hormone (LH) surges by competitively blocking GnRH receptors in the pituitary gland. This specific protocol was evaluated in a randomized study sponsored by **Bioroma** to compare its efficacy against traditional daily FSH and GnRH agonist regimens, particularly in 'poor responder' patients who typically face challenges in achieving adequate ovarian response.

Brand names

Elonva

Other names

Long-acting FSH + GnRH antagonistCorifollitropin alfa + GnRH antagonist regimen